The recent study on the global influenza vaccine market covers an in-depth analysis of the market on the basis of vaccine technology, end-user, and geography.
According to the report titled “Global Influenza Vaccine Market - Forecasts from 2019 to 2024”, the market is expected to increase from US$5.209 billion in 2018 to US$7.547 billion by 2024, at a CAGR of 6.37 percent during the projected period.
The report is segmented by vaccine technology as Trivalent and Quadrivalent; by end-user as Children, Adolescents, Adults, and Elderly; and by geography as North America (USA, Canada, Mexico, and Others), South America (Brazil, Argentina, and Others), Europe (Germany, France, United Kingdom, Spain, and Others), Middle East and Africa (Saudi Arabia, Israel, and Others), and Asia Pacific (China, Japan, South Korea, India, and Others).
The global influenza vaccine market is poised to propel during the forecast period owing to the importance of vaccination in order to prevent infection and serious outcomes caused by influenza viruses.
These include elderly people (people of age 65 years or older), babies or young children (6-59 months), pregnant ladies, people suffering from cardiovascular diseases, individuals suffering with chest problems like asthma or bronchitis, people with kidney disease, diabetes patients, individuals taking steroids, people undergoing cancer treatment, people suffering from long-term illnesses reducing the functioning of body’s immune system, and healthcare workers.
Thus, this calls for a high demand for influenza or flu vaccines which help in reducing the infections caused by seasonal flu viruses, emanating the market growth during the forecast period.